Heterogeneous worldwide access and pricing of Tafamidis

Abdirahman Wardherea Cardiac Amyloidosis Program, Columbia University Irving Medical Center, NY, USAView further author information

Dimitrios Bampatsiasa Cardiac Amyloidosis Program, Columbia University Irving Medical Center, NY, USAView further author information

Nowell Fineb Libin Cardiovascular Institute, University of Calgary, Calgary, CanadaView further author information

Pablo Garcia-Paviac Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA, CIBERCV, and Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, SpainView further author information

Martha Grogand Director, Cardiac Amyloid Clinic, Division of Circulatory Failure, Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USAView further author information

Arnt V. Kristene Department of Cardiology, University of Heidelberg, Heidelberg, GermanyView further author information

Thibaud Damyf Cardiology Department and French National Reference Centre for Cardiac Amyloidosis, GRC Amyloid Research Institute and Clinical Investigation Centre 1430 at Hôpitaux Universitaires Henri-Mondor AP-HP, and IMRB, INSERM, Université Paris Est Creteil, Créteil, FranceView further author information

Yoshiki Sekijimag Shinshu University, Matsumoto, JapanView further author information

Mathew S. Maurera Cardiac Amyloidosis Program, Columbia University Irving Medical Center, NY, USACorrespondence[email protected]
View further author information

show all

References

Yamamoto H, Yokochi T. Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail. 2019; 6(6):1128–1139. doi: 10.1002/ehf2.12518.
PubMed Web of Science ®Google Scholar
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018; 379(11):1007–1016. doi: 10.1056/NEJMoa1805689.
PubMed Web of Science ®Google Scholar
Kazi DS, Bellows BK, Baron SJ, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation. 2020; 141(15):1214–1224. doi: 10.1161/CIRCULATIONAHA.119.045093.
PubMed Web of Science ®Google Scholar
Gurwitz JH, Maurer MS. Tafamidis-A pricey therapy for a not-so-rare condition. JAMA Cardiol. 2020; 5(3):247–248. doi: 10.1001/jamacardio.2019.5233.
PubMed Web of Science ®Google Scholar
Jacobson DR, Alexander AA, Tagoe C, et al. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African-Americans. Amyloid. 2015;22(3):171–174. doi: 10.3109/13506129.2015.1051219.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Heterogeneous worldwide access and pricing of Tafamidis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Heterogeneous worldwide access and pricing of Tafamidis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date